NLC Health Ventures in Amsterdam, in collaboration Verily (formerly Google LifeSciences) announced on Monday the launch of Exolvo Biosciences. This biotech company provides solutions for biologic drug release.

NLC aims to advance drug delivery technologies through Exolvo. These technologies were developed within Verily, and are now being spun off as a private early-stage venture by NLC.

Exolvo’s oral drug delivery system is distinguished by its modular design and flexible capsule size, which allows it to adapt to a wide range of large molecular structure.

“This technology has the potential to have a significant impact. “This technology will improve the treatment experience for patients and make it easier for healthcare workers to deliver care.

Exolvo Biosciences: A Needful Innovation

Oral delivery of biologic drugs is difficult due to their size and complexity.

In order to avoid painful and frequent injections, biologic drugs are often administered intravenously or through frequent needle injections.

These treatments can be costly and burdensome to patients, as well as for the healthcare system.

“Talk to anyone who has a chronic disease such as diabetes and they’ll mention the struggle to have to inject themselves, in some cases even multiple times per day. Brian Longstreet, CEO and co-founder of Exolvo, says that there is a need to develop innovative solutions that make chronic disease treatments more accessible and less invasive.

Exolvo Biosciences, a biotech firm, aims to transform oral delivery of large complex molecules.

Exolvo, using Verily’s technology aims to transform the delivery of biological drugs to make treatments more affordable and less invasive.

Exolvo’s technology is making significant progress in assembling a IND (Investigational New Drug package) in the U.S., while actively engaging with key biotech and pharmaceutical partners.

NLC Health Ventures is an active investor in health technology

Based in Amsterdam, NLC Healthcare Ventures has become the largest healthtech venture builder and most active investor in Europe.

NLC identifies, develops, and scales transformative innovations in health care to provide quality care to more patients.

NLC is a ‘BCorp’, its funds comply with SFDR9 and contribute to ESG 3, 9 and 17.

They bring innovative innovations to patients at a large scale with more than 100 startups, four funds and activities in 16 countries.

The NLC Health Impact Fund, NLC’s largest and newest fund to date, invests in NLC startups. The fund provides capital to ventures at different stages, including initial and follow-up financing.